It inhibits epithelial–mesenchymal transition by modulating STAT3-chemokine (C–C motif) ligand 2 (CCL2) pathway in human bladder cancer 5637, BFTC and T24 cells [531], and suppresses cell proliferation and migration via forkhead box protein M1 (FoxM1) down-regulation in human gastric cancer SGC-7901 cells [514]. This evidence concerns the gene FOXM1 and urinary bladder cancer.